The aryl hydrocarbon receptor mediates raloxifene-induced apoptosis in estrogen receptor-negative hepatoma and breast cancer cells
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Identification of new molecular targets for the treatment of breast cancer is an important clinical goal, especially for triple-negative breast cancer, which is refractory to existing targeted treatments. The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor known primarily as the mediator of dioxin toxicity. However, the AhR can also inhibit cellular proliferation in a ligand-dependent manner and act as a tumor suppressor in mice, and thus may be a potential anticancer target. To investigate the AhR as an anticancer target, we conducted a small molecule screen to discover novel AhR ligands with anticancer properties. We identified raloxifene, a selective estrogen receptor (ER) modulator currently used in the clinic for prevention of ER-positive breast cancer and osteoporosis in post-menopausal women, as an AhR activator. Raloxifene directly bound the AhR and induced apoptosis in ER-negative mouse and human hepatoma cells in an AhR-dependent manner, indicating that the AhR is a molecular target of raloxifene and mediates raloxifene-induced apoptosis in the absence of ER. Raloxifene selectively induced apoptosis of triple-negative MDA-MB-231 breast cancer cells compared with non-transformed mammary epithelial cells via the AhR. Combined with recent data showing that raloxifene inhibits triple-negative breast cancer xenografts in vivo (Int J Oncol. 43(3):785-92, 2013), our results support the possibility of repurposing of raloxifene as an AhR-targeted therapeutic for triple-negative breast cancer patients. To this end, we also evaluated the role of AhR expression on survival of patients diagnosed with breast cancer. We found that higher expression of the AhR is significantly associated with increased overall survival and distant metastasis-free survival in both hormone-dependent (ER-positive) and hormone-independent (ER and progesterone receptor (PR)-negative) breast cancers. Together, our data strongly support the possibility of using the AhR as a molecular target for the treatment of hormone-independent breast cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Györffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169 · cited 2×
“The effect of AhR expression on relapse-free survival in patients with ER-negative and -positive breast cancer was evaluated by Kaplan–Meier analysis using the online tool KMPLOT based on the updated 2012 data set.(38) Data for AhR was accessed using AffymetrixID probe 202820_at.”
MethodDenison, M. S., & Nagy, S. R. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.135828 · Cited by 1,895 · cited 11×
“A structurally diverse array of small molecules, some of which are used in the clinic, have been shown to be ligands of the AhR.(14,15,19,46) Likewise,”
BackgroundInfluentialThe Aryl Hydrocarbon Receptor Complex and the Control of Gene Expression
Beischlag, T. V., Morales, J. L., Hollingshead, B. D., & Perdew, G. H. (2008) · Critical Reviews™ in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v18.i3.20 · Cited by 727 · cited 1×
“Upon ligand-binding, the AhR dissociates from chaperone proteins HSP90 and XAP2,(1) translocates from the cytosol to the nucleus, and heterodimerizes the AhR nuclear translocator (ARNT) to regulate AhR target genes containing functional xenobiotic response elements (XREs).(1) The role of the AhR in carcinogenesis cont…”
BackgroundMimura, J., Yamashita, K., Nakamura, K., Morita, M., Takagi, T. N., Nakao, K., Ema, M., Sogawa, K., Yasuda, M., Katsuki, M., et al. (1997) · Genes to Cells · doi:10.1046/j.1365-2443.1997.1490345.x · Cited by 626
Bisson, W. H., Koch, D. C., O’Donnell, E. F., Khalil, S. M., Kerkvliet, N. I., Tanguay, R. L., Abagyan, R., & Kolluri, S. K. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900199u · Cited by 149 · cited 5×
“Molecular Docking of AHR agonists TCDD and raloxifene was performed as described previously.(33) In the ICM-VLS (Molsoft ICM)-screening procedure, the ligand scoring is optimized to obtain maximal separation between the binders and non-binders.”
MethodSelf-citationBunger, M. K., Glover, E., Moran, S. M., Walisser, J. A., Lahvis, G. P., Hsu, E. L., & Bradfield, C. A. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn149 · Cited by 139
The Anti-Inflammatory Drug Leflunomide Is an Agonist of the Aryl Hydrocarbon Receptor
O'Donnell, E. F., Saili, K. S., Koch, D. C., Kopparapu, P. R., Farrer, D., Bisson, W. H., Mathew, L. K., Sengupta, S., Kerkvliet, N. I., Tanguay, R. L., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013128 · Cited by 124
Self-citationAHR2 Mutant Reveals Functional Diversity of Aryl Hydrocarbon Receptors in Zebrafish
Goodale, B. C., La Du, J. K., Bisson, W. H., Janszen, D. B., Waters, K. M., & Tanguay, R. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029346 · Cited by 89
Self-citationAnalysis of the Aryl Hydrocarbon Receptor (AhR) Signal Transduction Pathway
Denison, M. S., Rogers, J. M., Rushing, S. R., Jones, C. L., Tetangco, S. C., & Heath‐Pagliuso, S. (2002) · Current Protocols in Toxicology · doi:10.1002/0471140856.tx0408s11 · Cited by 55
Cited by
Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
Cheong, J. E., & Sun, L. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.11.007 · Cited by 487
Perkins, A., Phillips, J., Kerkvliet, N., Tanguay, R., Perdew, G., Kolluri, S., & Bisson, W. (2014) · Biology · doi:10.3390/biology3040645 · Cited by 52
Self-citationBonati, L., Corrada, D., Giani Tagliabue, S., & Motta, S. (2017) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2017.01.011 · Cited by 27
Faber, S., Lahoti, T., Taylor, E., Lewis, L., Sapiro, J., Toledo Sales, V., Dragan, Y., & Jeffy, B. (2022) · Cells · doi:10.3390/cells11101708 · Cited by 16
Metadata
- Authors
- O'Donnell, E. F., Koch, D. C., Bisson, W. H., Jang, H. S., & Kolluri, S. K.
- Venue
- Cell Death & Disease
- Published
- 2014-01-30
- Volume
- 5
- Issue
- 1
- Pages
- e1038-e1038
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W2094760916
- Cited by
- 102
- References
- 9
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.